WAGS Stung by $50 million Anti-Kickback Penalty
The past year has brought rough financial seas to Walgreens. As recently as this January we reported on Walgreens plans to possibly go private after closing
May 20, 2025
The past year has brought rough financial seas to Walgreens. As recently as this January we reported on Walgreens plans to possibly go private after closing
Today’s Report spotlights a relatively insignificant event in therapy distribution. We are talking about COSTCO, yes the warehouse retailer. What they did is simply add a new
The FDA recently approved one… no wait, two… no wait, is it really one times two denosumab biosimilars…..?? The/these approval/s include Ospomyv (denosumab-dssb) and Xbryk (denosumab-dssb)…
The FDA recently approved a new ORAL therapy, Romvimza (vimseltinib) from Deciphera Pharmaceuticals, LLC, indicated for adult patients with symptomatic tenosynovial giant cell tumor (TGCT)
How do you validate value? How do you demonstrate the ability to ‘walk the talk’? The National Association of Specialty Pharmacy (NASP) has taken its
Following what seems to be a new trend, the FDA has approved yet another 20+ year old therapy based on a major remodel… this one
The FDA recently approved a new therapy originally approved in 2006, Susvimo (ranibizumab) from Genentech, an ocular implant providing customized therapy for diabetic macular edema
The FDA recently approved another biosimilar, Avtozma (tocilizumab-anoh) from Celltrion, as a third biosimilar to Actemra. As with the reference brand, Avtozma is indicated for the
The FDA recently approved a very old drug, Spravato (esketamine) from Janssen Pharmaceuticals, for a very new indication. Esketamine was originally approved by the FDA
Announcements for newly approved specialty drugs often state that the product will be available through specialty pharmacy in limited distribution. However, the early press releases
